Biotechnology company Maxion Therapeutics has been awarded a £2 million grant from Innovate UK, as part of its Biomedical Catalyst 2022 Round 2: Industry-led R&D funding competition. The funds will support the use of Maxion’s proprietary KnotBody platform www.maxiontherapeutics.com/#technology to develop antibodies to treat autoimmune diseases (AID) with high unmet clinical need.
The funding follows Maxion’s Series A financing round in February 2023 from which it raised £13 million.
The effective treatment of AID remains an important medical challenge and a significant area of unmet medical need. Currently, 4% of the world’s population, or around 300 million people, are thought to be suffering from over 80 different autoimmune conditions. In the UK alone, 4 million people live with an autoimmune condition, with the incidence increasing by 3-9% annually.
Antibody-based therapies have transformed the way chronic conditions like autoimmune disorders are treated, providing enhanced efficacy and safety while reducing the need for frequent administration. However, despite the success of current antibody therapies such as Humira, a significant proportion of patients do not respond well to treatment. Moreover, these therapies can lead to broad immunosuppression, increasing the risk of infections. As such, novel treatments are required that can offer broader patient coverage while minimising adverse effects.